InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies

Biotech Begins to Demonstrate Strategy to Expand NHL

18-Sep-2008 - InNexus Biotechnology Inc. announced the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model. InNexus plans to submit the data for publication along with additional data from animal studies recently completed and ...

InNexus Biotechnology Announces an Expansion of its SuperAntibody R&D Program

18-Mar-2005 - InNexus Biotechnology Inc. announced the extension and expansion of its research and development program for SuperAntibody Technology (SAT) by expanding its R&D facilities within the Kentucky Technology Center on the Coldstream Research Campus in Lexington, Kentucky. This modern laboratory ...

InNexus Announces Achieving Business Milestone in Development of Intracellular SuperAntibody(TM) Therapeutics

17-Mar-2005 - InNexus Biotechnology Inc. announced the achievement of a business milestone in the development of intracellular SuperAntibody(TM) therapeutics. With the receipt of the first of three high affinity anti-apoptosis monoclonal antibodies from its co-development partner, Epitomics, Inc., InNexus has ...

InNexus to Develop SuperAntibody for Treatment of Coronary Heart Disease (Plaque)

14-Oct-2004 - InNexus Biotechnology, Inc. is pleased to announce that it has received approval from the TSX Venture Exchange for the acquisition of monoclonal antibodies and related intellectual property from ImmPheron Inc. of Lexington, Kentucky. InNexus intends to initiate the product development of the ...